Tag Archives: bleeding

ACC 2019 | SAFARI: sorpresivamente, el acceso radial no ofrece ventajas en el infarto

ACC 2019 | SAFARI: Unexpectedly, Radial Approach Offers No Benefits In STEMI

ACC 2019 | SAFARI: Unexpectedly, Radial Approach Offers No Benefits In STEMI

This study was not able to show benefits in terms of mortality or bleeding when using radial vs. femoral approach in patients undergoing ST elevation myocardial Infarction. This small trial does not change things for “radialists” way past their learning curve who already feel confident with this technique. For them, there is no way back.

ARTE: ¿AsEl fin de la aspirina para los pacientes anticoagulados que reciben angioplastiapirina o aspirina más clopidogrel post TAVI?

Aspirin, Bleeding and Cardiovascular Events in Healthy Elderly

The ASCEND and ARRIVE trials -presented at the European Cardiology Congress and published in The New England Journal of Medicine (NEJM) and The Lancet respectively- have put against the ropes the indication of aspirin in the context of primary prevention. The ASPREE trial, recently published in the NEJM, appears to have definitely overthrown aspirin, since

TCT 2018 | LEADERS FREE II: DES sin polímero en alto riesgo de sangrado con 1 mes de antiagregación

TCT 2018 | LEADERS FREE II: Polymer-Free DES in Patients at High Risk for Bleeding with 1 Month of Antiplatelet Therapy

This study was aimed at gaining device registration from the US Food and Drug Administration (FDA) for a polymer-free biolimus A9 drug-coated stent (BioFreedom, Biosensors). The study had two purposes: on the one hand, it meant to reproduce the results of the LEADERS FREE trial (published in 2015) in terms of safety and efficacy with

Mortalidad y volumen de angioplastias de un centro ¿Tienen relación?

The Dangerous Combination of Complex Angioplasty and High Bleeding Risk Seems to Have a Solution

The LEADERS FREE trial demonstrated that a polymer-free Biolimus A9-coated stent (BioFreedom™DCS; Biosensors Europe, Morges, Switzerland) is superior to a conventional stent (bare metal stent, BMS) in patients with high bleeding risk treated with only one month of dual antiplatelet therapy. Now, is this global study outcome applicable in cases of complex lesions with several

EuroPCR 2018 | LEADERS FREE: angioplastias complejas en pacientes con alto riesgo de sangrado

EuroPCR 2018 | LEADERS FREE: Complex Angioplasty in Patients with High Risk for Bleeding

The LEADERS FREE study showed that a biolimus A9-coated polymer-free stent was superior to a conventional stent in terms of safety and efficacy in patients who received dual antiplatelet therapy for only a month due to their high risk for bleeding. In this substudy, researchers analyzed 667 patients enrolled in the original LEADERS FREE trial who met certain requirements

ACC 2018 | TREAT: Ticagrelor + Fibrinolytics’ Effect on Bleeding

Ticagrelor seems as safe as clopidogrel in patients undergoing ST elevation MI treated with fibrinolytics, at least in terms of TIMI major bleeding at 30 days. Longer follow up will help determine whether there are differences in efficacy or safety issues, as stated by the presenter Otavio Berwanger. This study was presented at ACC 2018 scientific sessions

Doble antiagregación: menos es más en añosos.

Dual Antiplatelet Therapy: Less Is More for Elderly Patients

A recent meta-analysis that will be published soon in JACC Intv offers evidence of benefit derived from short-term dual antiplatelet therapy for elderly patients. This is a patient group that has always been excluded from the major trials, while remaining one of the most challenging subgroups in which to balance bleeding and ischemic risks. The

El acceso cubital puede ser un as en la manga extra antes de pensar en el femoral

Transulnar Access: Another Ace Up Our Sleeve Before Transfemoral Access

Transulnar access can be as safe and effective as transradial access, and it is a particularly good alternative for the preservation of radial artery patency or when such vessel presents a difficult anatomy. This new meta-analysis that will be published soon in Catheter Cardiovasc Interv showed a relatively high failure rate for that access, but

Riesgo isquémico y riesgo de sangrado luego de una angioplastia primaria

Ischemic and Bleeding Risk After Primary Angioplasty

Patients with ST-segment elevation myocardial infarction who undergo primary angioplasty are at high risk for both ischemic and bleeding events, which affect significantly both morbidity and mortality. An optimal selection of antithrombotic therapies in terms of strength and duration must take into account the timing for the procedure, since the risk for these complications may

Top